Eculizumab therapy for atypical haemolytic uraemic syndrome due to a gain-of-function mutation of complement factor B

Pediatric Nephrology

Volumn 28, Issue 8, 2013, Pages 1315-1318

  Gilbert, Rodney D ^a   Fowler, Darren J ^a   Angus, Elizabeth ^a   Hardy, Stephen A ^b   Stanley, Louise ^b   Goodship, Timothy H ^c  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^b NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Atypical haemolytic uraemic syndrome; Complement activation; Complement factor B; Eculizumab; Gain of function mutation

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; ECULIZUMAB;

ARTICLE; BLOOD TRANSFUSION; CASE REPORT; CLINICAL FEATURE; FEMALE; GAIN OF FUNCTION MUTATION; GENE AMPLIFICATION; GENE SEQUENCE; HEMOLYTIC UREMIC SYNDROME; HUMAN; HUMAN TISSUE; INFANT; PRIORITY JOURNAL; RESUSCITATION; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL MARKERS; BIOPSY; COMPLEMENT FACTOR B; COMPLEMENT MEMBRANE ATTACK COMPLEX; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HEMOLYTIC-UREMIC SYNDROME; HUMANS; IMMUNOLOGIC FACTORS; INFANT; L-LACTATE DEHYDROGENASE; MUTATION; PHENOTYPE; TREATMENT OUTCOME;

EID: 84879957846     PISSN: 0931041X     EISSN: 1432198X     Source Type: Journal    
DOI: 10.1007/s00467-013-2492-x     Document Type: Article

References (12)

1. Loirat C, Frémeaux-Bacchi V (2011) Atypical hemolytic uremic syndrome. Orphanet J Rare Dis 6:60
2. Maga TK, Nishimura CJ, Weaver AE, Frees KL, Smith RJH (2010) Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome. Hum Mutat 31:E1445-E1460
3. Bexborn F, Andersson PO, Chen H, Nilsson B, Nilsson Ekdahl K (2008) The tick-over theory revisited: formation and regulation of the soluble alternative complement C3 convertase (C3(H2O)Bb). Mol Immunol 45:2370-2379
4. Joiner KA (1988) Complement evasion by bacteria and parasites. Annu Rev Microbiol 42:201-230
5. Ricklin D (2012) Manipulating the mediator: modulation of the alternative complement pathway C3 convertase in health, disease and therapy. Immunobiology 217:1057-1066
6. de Jorge EG, Harris C, Esparza-Gordillo J, Carreras L, Arranz EA, Abarrategul G, López-Trascasa M, Sánchez-Corral P, Morgan BP, de Córdoba SR (2007) Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc Natl Acad Sci USA 104:240-245
7. Besbas N, Gulhan B, Karpman D, Topaloglu R, Duzova A, Korkmaz E, Ozaltin F (2013) Neonatal onset hemolytic uremic syndrome successfully treated with eculizumab. Pediatr Nephrol 28:155-158
8. Cavci FS, Cakar N, Hancer VS, Uncu N, Acar B, Gur G (2012) Eculizumab therapy in a child with hemolytic uremic syndrome and CFI mutation. Pediatr Nephrol 27:2327-2331
9. Al-Akash SL, Almond PS, Savill VH Jr, Gharaybey SL, Hogue C (2011) Eculizumab induces long-term remission in recurrent post transplant HUS associated with C3 gene mutation. Pediatr Nephrol 26:613-619
10. Châtelet V, Lobbedez T, Frémeaux-Bacchi V, Ficheux M, Ryckelynck JP, Hurault de Ligny B (2010) Eculizumab: safety and efficacy after 17 months of treatment in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome: case report. Transplant Proc 42:4353-4355
11. Salem G, Flynn J, Cataland SR (2013) Profound neurological injury in a patient with atypical hemolytic uremic syndrome. Ann Hematol 92:557-558
12. Malina M, Gulati A, Bagga A, Majid MA, Simkova E, Schaefer F (2013) Peripheral gangrene in children with atypical hemolytic uremic syndrome. Pediatrics 131:e331-e335